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Abstract
Human leukocyte antigen G (HLA-G) molecules cor-
responding to nonclassic class I genes of the major
histocompatibility complex exhibit immunomodulatory
properties. They are either membrane-bound or solubly
expressed during certain tumoral malignancies. Solu-
ble human leukocyte antigen G (sHLA-G) molecules
seem more frequently expressed than membrane-
bound isoforms during hematologic malignancies,
such as lymphoproliferative disorders. Assay of these
molecules by enzyme-linked immunosorbent assay in
patients suffering from another hematologic disorder
(acute leukemia) highlights increased sHLA-G secre-
tion. This increased secretion seems more marked in
acute leukemia subtypes affecting monocytic and lym-
phoid lineages such as FABM4 and FABM5, as well
as both B and T acute lymphoblastic leukemia (ALL).
Moreover, this study uses in vitro cytokine stimula-
tions and reveals the respective potential roles of
granulocyte–macrophage colony-stimulating factor
and interferon-; in increasing this secretion in FABM4
and ALL. Correlations between sHLA-G plasma level
and clinical biologic features suggest a link between
elevated sHLA-G level and 1) the absence of anterior
myelodysplasia and 2) high-level leukocytosis. All
these findings suggest that sHLA-G molecules could
be a factor in tumoral escape from immune survey
during acute leukemia.
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Introduction
Human leukocyte antigen G (HLA-G) is a nonclassic major
histocompatibility complex class I gene encoding for a pro-
tein with a cytoplasmic tail that is shorter than those of
its classic counterparts [1], showing restrictive distribution
[2–4] and lower polymorphism [5]. By alternative splicing,
the HLA-G gene generates seven transcriptional isoforms
encoding four membrane-bound protein isoforms (HLA-G1,
HLA-G2, HLA-G3, and HLA-G4) [6,7] and three soluble iso-
forms (HLA-G5, HLA-G6, andHLA-G7) [8,9]. Membrane-bound
HLA-G isoforms are expressed by extravillous cytotrophoblast
cells [4], fetal capillary endothelial cells [2], endovascular cells
[10], and thymic epithelium cells [3]. They can also be detected
in tumoral pathologies such as melanomas [11]; breast [12],
renal [13], and lung carcinomas [14]; gliomas [15]; and cu-
taneous lymphomas [16].
HLA-G is the only class I gene that allows the generation of
a spliced transcript with the persistence of intron 4 or intron 2
containing a stop codon, thus preventing translation upstream
of the intracytoplasmic domain. It has also been shown that
a shedding form of HLA-G1 protein (sHLA-G1) [17,18], which
is cleaved by metalloproteinases, coexists with HLA-G5 sol-
uble isoforms generated by the translation of spliced mRNA
[17]. HLA-G5 is composed of a1, a2, and a3 domains, whereas
HLA-G6 is composed of a1 and a3 domains, allowing an asso-
ciation with light-chain b2-microglobulin and CD8 molecules. A
new variant, HLA-G7, has been recently described. This var-
iant is composed of a1 domains only, but little is known about
its functions [9]. HLA-G5 is the full-length soluble isoform, in
the same way that HLA-G1 is for membrane-bound isoforms,
and it has the same properties as those of other soluble iso-
forms. Interest in soluble human leukocyte antigen G (sHLA-G)
molecules is constantly growing. Indeed, sHLA-G molecules
are expressed during pregnancy by cytotrophoblast cells in-
vading the maternal decidua and are secreted by villous tro-
phoblasts [19]. Basal plasma level has been detected in
amniotic fluid and in healthy subjects, without any difference
between the sexes [20]. Secretion of sHLA-G isoforms could
be detected in the sera of heart-transplanted patients and
during tumoral pathologies. Secretion has been observed in
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ascites of patients suffering from ovarian and breast carci-
nomas [21] and melanomas [22]. However, the cell type re-
sponsible for the secretion has not yet been defined,
although monocytes are considered as good candidates
under physiological conditions. An increase in sHLA-G se-
cretion has also been detected in the plasma of patients who
have developed B or T non-Hodgkin lymphoma (NHL) [23].
The immunomodulatory role of HLA-G is well-known in
the context of pregnancy, as well as during immune reactions
through interactions with inhibitory receptors. HLA-G1 has
been demonstrated to inhibit cytotoxic lysis by NK cells,
as well as by lymphocyte T CD8+ cells through direct inter-
actions with ILT-2 and p49KIR2DL4 receptors [24–27] or
through indirect interactions with CD94/NKG2A after induc-
tion of HLA-E expression [28]. Moreover, sHLA-G isoforms
appear to be able to induce the apoptosis of CD8+ T cells
through ligation with CD8 [29], a characteristic shared with
classic soluble HLA class I molecules, according to some
authors [30,31]. HLA-G1 and HLA-G5 are also capable of: 1)
inhibiting the allogeneic proliferation of Tcells [32,33]; 2) inter-
fering with the priming of naive CD8+ T cells; and 3) inhibiting
allogeneic lysis in gliomas and myoblast models [15,34,45].
Soluble proteins seem to be more frequently expressed
than membrane-bound isoforms in hematologic malig-
nancies, as demonstrated for lymphoproliferative disorders
[23]. This study aims to investigate the expression of sHLA-G
in another hematologic tumoral process affecting less ma-
ture cells—acute leukemia. This tumoral process comprises
the proliferation of immature and undifferentiated hemato-
poietic cells called blasts, which induces the blockage of
normal hematopoietic differentiation. Some subtypes of
these pathologies, such as clonal hematopoietic disorders
characterized by cytopenia and bone marrow dysplasia, can
also be associated with myelodysplasia. This results from
the proliferation, differentiation, and apoptotic processes of
hematopoietic precursors, often evolving into acute myeloid
leukemia. Acute leukemia subtypes have been classified
according to the French–American–British (FAB) classifica-
tion and more recently according to the World Health Orga-
nization classification. This study focuses on six FAB subtypes
of acute leukemia, using a classification routinely adopted on
diagnosis for the period considered: 1) four acute myeloblastic
leukemia (AML) subtypes: FABM1 (myeloblastic leukemia
without maturation), FABM2 (myeloblastic leukemia with
maturation), FABM4 (myelomonocytic leukemia), and FABM5
(monocytic leukemia); and 2) T or B acute lymphoblastic leu-
kemias (ALLs) (B-ALL and T-ALL). In one of our previous
studies, we showed that HLA-G is transcribed in 2 of 13 cases
of acute leukemia characterized by a monocytic contingent
[35]. In a subsequent study, no HLA-G surface or cytoplasm
expression was detected in normal or malignant cells, includ-
ing 17 AML and 15 ALL cases [36]. Moreover, some authors
have failed to find surface HLA-G expression in leukemic cells
without incubation using interferon-g (IFN-g) [37], whereas
others have not detected any HLA-G expression at all [38].
Because we previously found an increase of sHLA-G mole-
cules in mature lymphoid malignancies [39], contrasting with
the absence of cell surface expression, this study focuses
on the expression of sHLA-G molecules in immature he-
matopoietic malignancies (i.e., acute leukemia). We also in-
vestigate here the impact of cytokine microenvironment on
sHLA-G secretion, based on previous studies performed on
the U937 cell line [36], T-NHL cells [23], pulmonary tumors
[14], and cutaneous lymphomas [16]. In this study, the sera of
patients suffering from acute leukemia were assayed by the
enzyme-linked immunosorbent assay (ELISA) sandwich
method, yielding increased sHLA-G levels for both AML and
ALL pathologies and being evenmoremarked for FABM4 and
FABM5 as well as for B-ALL and T-ALL. The study of cytokine
impact revealed a potential role of granulocyte–macrophage
colony-stimulating factor (GM-CSF) and IFN-g in AML and
ALL pathologies, respectively, in controlling the increase in
sHLA-G levels. We also established correlations between
elevated levels of sHLA-G and two clinical biologic criteria
(myelodysplasia and leukocytosis).
Methods
Patients
Seventy-five patients suffering from acute leukemia who
were treated at the Department of Hematology, Rennes Hos-
pital, were included in this retrospective study (between Feb-
ruary 2001 and April 2004). The pathologies were classified
according to the system used at that time (i.e., FAB classifica-
tion): 47 patients suffered from AML (7 with FABM1, 27 with
FABM2, 7 with FABM4, and 6 with FABM5) and 28 patients
suffered from ALL (11 with B-ALL and 17 with T-ALL). Plasma
samples were obtained from EDTA-anticoagulated blood
after centrifugation (1000g) at 4jC and then cryopreserved
at 80jC. Plasma from healthy subjects (n = 37) was pur-
chased from the Etablissement Franc¸ais du Sang Bretagne
(Rennes, France) and cryopreserved at 80jC before being
used as controls.
Cytokines
Interleukin (IL) 2 (107 U/mg), IFN-g (107 U/mg), and IL-10
(>5 105 U/mg) were supplied byTebu-Peprotech (LePerray-
en-Yvelines, France). Human GM-CSF (specific activity >
107 U/mg) was provided by Gentaur (Brussels, Belgium).
Cell Cultures
Mononuclear cell samples were obtained from 21 patients
suffering from AML and exhibiting high sHLA-G levels
(FABM1, n = 5; FABM2, n = 5; FABM4, n = 5; FABM5, n = 6)
and from 12 patients suffering from ALL (B-ALL, n = 6;
T-ALL, n = 6). Mononuclear cells from leukemic blood were
obtained by Ficoll density gradient centrifugation and cryo-
preserved at 196jC. Cell samples were made up of >80%
tumoral cells. Constant numbers of cells (1  106 ml1) were
cultured in six-well plates for 48 hours in a culture medium
(RPMI; Invitrogen,Carlsbad,CA) supplementedwith 10% fetal
bovine serum, 2 mM glutamine, 1% sodium pyruvate, and
penicillin–streptomycin. The cultures were prepared in the
presence or absence of different combinations of cytokines.
The cytokines were used at the following concentrations under
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different conditions: IFN-g alone (500 U/ml), IFN-g (500 U/ml)
with GM-CSF (100 U/ml), IFN-g (100 U/ml) with GM-CSF
(100 U/ml) and IL-2 (220 U/ml), and IL-10 alone (50 ng/ml).
RNA Isolation and Reverse Transcription Polymerase
Chain Reaction (PCR)
Total RNA was extracted from each culture condition
using TRI reagent (Euromedex, Mundolsheim, France), ac-
cording to the manufacturer’s recommendations. RNA was
then quantified by a spectrophotometer. cDNA synthesis was
performed using Superscript II Reverse Transcriptase (Invi-
trogen), according to the manufacturer’s recommendations.
Real-Time Quantitative PCR
cDNA of leukemic cells from all HLA-G isoform transcripts
were quantified by duplex PCR during 40 cycles in the pres-
ence of TaqMan Universal PCR Master Mix on an ABI prism
7000 instrument (AppliedBiosystems, FosterCity, CA), as pre-
viously described [40]. Human glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as endogenous control
(Applied Biosystems). All samples were analyzed in dupli-
cate. Quantification is given relative to transcripts levels of
JEG3, a cell line expressing HLA-G transcripts. The transcrip-
tion levelswere calculated as follows:DCt sample =Ct HLA-GCt
GAPDH and DDCt = DCt sample  DCt JEG3. The quantity of
HLA-G transcripts is defined by 2DDCt.
Specific sHLA-G ELISA
sHLA-G isoforms (HLA-G5 and sHLA-G1) were quanti-
fied using a specific sandwich ELISA, with MEM-G/9 and
anti–b2-microglubulin horseradish peroxidase as capture
and revelation antibodies, respectively, which were validated
at the ‘‘Wet Workshop for Quantification of Soluble HLA-G
in Essen, 2004’’ [41]. Standard curves were obtained by
the quantification of serial dilutions of calibrated superna-
tants of the LCL 721.221-G5 cell line and by validation by an
internal control consisting of another HLA-G5 sample of
known concentration that was purified as previously de-
scribed [33]. HLA-G concentrations of the samples were de-
termined from their optical densities in relation to standard
experimental curves.
Determination of Cytokine Profile in Plasma Samples
Levels of IL-10, IL-4, IL-6, IL-2, IFN-g, and tumor necrosis
factora (TNF-a) in the plasma of patients suffering fromacute
leukemia were determined using Cytometric Bead Array (BD
Biosciences, Mountain View, CA) on a FACSCalibur cytom-
eter (BD Biosciences).
Statistical Analysis and Clinical Biologic Correlations
The statistical tests used here (i.e., Student’s t test, Wil-
coxon matched-pair rank test, and Mann-Whitney U test) are
discussed in detail in Results. Correlations of clinical biologic
criteria with HLA-G levels were evaluated using one-way
analysis of variance (ANOVA). Tests were considered sig-
nificant when P < .05.
Results
sHLA-G Molecules Are Increased in the Plasma of Patients
Suffering from Acute Leukemias
The mean sHLA-G plasma level of healthy subjects (n =
37) is 16.23 ± 6.17 ng/ml. This level is considered as the
physiological level closest to that found in other ELISA
studies [22,42]. The threshold above which sHLA-G level is
considered pathologic in patients is defined as follows: mean
of control plasma level +2SD (>28.6 ng/ml). Quantitative vari-
ables are expressed as mean ± SEM. Differences between
healthy subjects and patients suffering from AML and ALL
are analyzed here using Student’s t test and are considered
as significant when P < .01. sHLA-G level means are sig-
nificantly increased for AML patients (n = 47; mean = 52.8 ±
32.7 ng/ml, P < .01) as well as for ALL patients (n = 28;
mean = 63.4 ±35.8 ng/ml, P < .001) (Figure 1). Thirty-five of
47 (74%) patients with AML are considered as pathologic,
according to their sHLA-G plasma level. Interestingly, FABM4
and FABM5 yield the highest means, with values of 81.4 ±
35.7 and 73.7 ± 33.5 ng/ml, respectively. In contrast, FABM1
andFABM2 levels (46.4 ± 33.3 and 42.6 ± 26.6 ng/ml, respec-
tively) are lower. All patients suffering from FABM4 and
FABM5 show crossing of their sHLA-G pathologic thresh-
old (Figure 2). In addition, 25 ALL patients (89%) display an
Figure 1. sHLA-G plasma levels of leukemic patients measured by specific ELISA compared with those of healthy subjects. Mean plasma levels ± SD (ng/ml) are
represented by histograms for healthy subjects (n = 37), AML (n = 47), and ALL (n = 28). Both AML (*P < .01) and ALL (**P < .001) show a significant increase in
sHLA-G level compared to that in controls, according to Student’s t test. AML = acute myeloblastic leukemia; ALL = acute lymphoblastic leukemia.
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increased sHLA-G plasma level. T-ALL cases exhibit more
elevatedmeans (i.e., 72.9 ± 39.6 ng/ml), and 16 of 17 patients
show an increase in their sHLA-G plasma level (Figure 2).
Seven of 11 patients suffering from B-ALL show an increased
sHLA-G level, but to a lesser extent with respect to the sHLA-
Gmean level (49.6 ± 24.6 ng/ml). Each of the sHLA-G plasma
levels for the different pathology subtypes is significantly
increased compared to those of controls (P < .001), except
for FABM1 (P = .03), according to the nonparametric Mann-
Whitney U test that is suitable for small sample sizes (signifi-
cant when P < .001).
sHLA-G Secretion Is Induced In Vitro after Cytokine
Stimulation of FABM4, T-ALL, and B-ALL Cells
An in vitro study was performed on cells provided by
patients selected for their high sHLA-G plasma levels. Dif-
ferent results are observed according to the subtype of AML
(Figure 3). We compare variations of sHLA-G secretion be-
tween untreated and cytokine-stimulated cells using the Wil-
coxon matched-pair signed rank test, which is suitable for
the analysis of paired variations in small sample sizes
(n < 20). P < .05 is considered significant.
Stimulation of peripheral bloodmononuclear cells (PBMC)
provided by nonselected healthy controls (n = 5) exhibiting
basal sHLA-G levels did not yield any significant increase in
sHLA-G levels compared with that in control conditions,
without any cytokine stimulation (Figure 3a). Cytokine stim-
ulation of FABM1 (n = 5) and FABM2 (n = 5) cells failed to
produce any increase in sHLA-G secretion compared to
that in controls corresponding to nonstimulated leukemic
cells, under any of the tested conditions (Figure 3b). By con-
trast, stimulation of FABM4 cells (n = 5) led to a significant
increase in sHLA-G secretion compared to that in controls
(11.8 ng/ml), in the presence of IFN-g and GM-CSF (29.6 ng/
ml) or with IL-10 alone (28.1 ng/ml). Although we observed an
increase in sHLA-G level in the presence of IFN-g, GM-CSF,
and IL-2 (31 ng/ml), it remains nonsignificant. However,
FABM5 cells (n = 4) do not seem to react in the presence of
any of the tested cytokines. We also observed that leuke-
mic cells from the lymphoid lineage are sensitive to in vitro
cytokine stimulation. Both B-ALL and T-ALL show signifi-
cant responses in terms of their sHLA-G secretion com-
pared to that in controls, as illustrated in Figure 3c (three- to
four-fold increase), except for conditions with IL-10 or IFN-g
stimulation on B-ALL (increase from 7.45 to 19.4 ng/ml, al-
though nonsignificant).
The results obtained from transcript level studies also
show an increase in the HLA-GmRNA level compared to that
in controls. The stimulation was performed using reactive
cells tested for sHLA-G secretion (FABM4, B-ALL, and
T-ALL), as illustrated in Figure 4a. In contrast, nonrespond-
ing pathologies tested for secretion (FABM1, FABM2, and
FABM5) failed to show any increase in the HLA-G mRNA
level, whatever the situation (Figure 4b).
Cytokine Profile in the Studied Pathologies
The specific cytokine profile Th1/Th2 (levels of IL-2,
IFN-g, TNF-a, IL-4, IL-6, and IL-10) was evaluated for all
patients included in the sHLA-G level study. Except for a few
patients with detectable levels of plasma IL-6, IL-10, and,
sometimes, IFN-g, the analysis failed to show any correla-
tion between these levels and the pathology subtype or the
HLA-G plasma level. However, TNF-a and IL-2 were de-
tected in none of the patients.
Clinical Biologic Correlations
We performed one-way ANOVA between the HLA-G
plasma levels of patients and relevant clinical biologic crite-
ria for leukemias. No correlation was found with remission
delay, occurrence of relapse, or death. However, ANOVA sta-
tistics reveal a highly significant relationship between ele-
vated sHLA-G plasma levels and the absence of anterior
myelodysplasia (P < .01) (Figure 5a), along with high-level
leukocytosis (P < .01) (Figure 5b).
Discussion
In this retrospective study, we report that sHLA-G molecules
increase in patients suffering from different acute leukemia
subtypes. We also show that the cytokine environment is
able to stimulate sHLA-G secretion by pathologic cells in an
in vitro model, but in a differential way according to cell line-
age. Previous studies on HLA-G expression in leukemic pa-
thologies have provided discordant conclusions. We confirm
the results of other authors who have not found membrane-
bound or cytoplasmic HLA-G expression [36,38]. sHLA-G
isoforms seem to be more frequent than membrane-bound
isoforms in solid tumors (ovarian and breast cancer ascites),
as well as in hematopoietic malignancies such as lympho-
proliferative disorders [23,39].
Higher HLA-G levels were found in ALL and are compati-
ble with previous data obtained on lymphoproliferative dis-
Figure 2. Plasma levels of sHLA-G as a function of acute leukemia subtype.
Each dot represents a plasma level of one patient measured by specific ELISA.
The horizontal line represents the sHLA-G positivity threshold defined by the
mean of the sHLA-G level of healthy subjects (n = 37) +2 SD (28.6 ng/ml).
Horizontal bars represent mean plasma levels for each pathology. sHLA-G plas-
ma levels considered as pathologic are distributed as follows: 4 of 7 for FABM1,
18 of 27 for FABM2, 7 of 7 for FABM4, 6 of 6 for FABM5, 7 of 11 for B-ALL, and
16 of 17 for T-ALL. All subtypes show significantly increased sHLA-G levels,
according to the Mann-Whitney U test (P < .001), except for FABM1 (P = .03).
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orders. Moreover, T CD4+ lymphocytes were demonstrated
as potential sHLA-G secretors during mixed allogeneic re-
actions [32], as well as in one case of Sezary syndrome
(T cutaneous lymphoma) [23]. High sHLA-G plasma level in
T lineage (72.9 ng/ml) corresponds to five times the physio-
logic level. FABM4 and FABM5, which correspond to mye-
lomonocytic or monocytic proliferation, equally exhibit high
sHLA-G levels (81.4 and 73.7 ng/ml, respectively). These
findings are also consistent with speculations on the type
of secreting cells. Under physiological conditions, monocytes
are suspected to be the main sHLA-G secretors [43]. In ad-
dition, other cells from monocytic lineage, such as myeloid
dendritic cells, are able to secrete HLA-G molecules [33].
Previous transcriptional studies on leukemia support these
two statements because only lymphoid and monocytic tu-
moral cells are able to express HLA-G transcripts [35].
In vitro cytokine stimulations of leukemic cells show an
effect of the previously described cytokines, alone or in com-
bination (IFN-g, GM-CSF, IL-2, or IL-10), on sHLA-G se-
cretion. This ability to induce HLA-G expression has been
demonstrated in the myelomonocytic cell line U937 for
membrane-bound expression [36]. Moreover, the same phe-
nomenon has been observed in T-NHL cells [23]. Other
teams have induced HLA-G expression on the surface of
myeloblastic leukemia cells by IFN-g stimulation [37]. This
latter result is subject to debate due to lack of incubation
with AB serum, as suggested by Polakova et al. [38]. It seems
that IFN-g preferentially activates HLA-G secretion in ALL
cells. Sensitivity to IFN-g regarding HLA-G expression has
been previously reported in human gliomas [15], ovarian
carcinoma cells [44], and myoblast models [45], as well
as in monohistiocytic cell lines [36]. The effect of IFN-g on
HLA-G transcription might appear surprising because the
common classic HLA class I interferon-stimulating response
element (ISRE) is truncated in the HLA-G gene. Neverthe-
less, a functional ISRE upstream of the promoter region of
HLA-G gene could explain the action of IFN-g [46,47]. How-
ever, no exact correlation can be established under each
Figure 3. sHLA-G levels of culture supernatants measured by specific ELISA with or without 48 hours of cytokine stimulation of acute leukemia cells. Histograms
represent sHLA-G levels (ng/ml) ± SE for the following conditions: (1) control (without stimulation); (2) IFN-c (500 U/ml); (3) IFN-c (500 U/ml) + GM-CSF (100 U/ml);
(4) IFN-c (100 U/ml) + GM-CSF (100 U/ml) + IL-2 (220 U/ml); (5) IL-10 (50 ng/ml). (a) Stimulation of PBMC from healthy donors. No sHLA-G secretion increase is
observed whatever the condition. (b) Stimulation of AML cells. Only FABM4 shows a significant increase in sHLA-G secretion (*P < .05) for conditions (3) and (5),
according to the Wilcoxon paired test. FABM1, FABM2, and FABM5 cell stimulations do not yield any increase in sHLA-G level compared to that in controls. (c)
Stimulation of ALL cells. B-ALL and T-ALL show a significant increase in sHLA-G secretion (*P < .05) for conditions (3) and (4) compared to that in controls. In
addition, T-ALL cells stimulated under condition (2) show a significant increase in sHLA-G secretion (P < .05).
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condition at the level of soluble proteins and transcripts, sug-
gesting that posttranscriptional mechanisms are involved, as
previously described [14].
GM-CSF and IL-10 exert an influence on HLA-G se-
cretion for FABM4 cells, in contrast to FABM5. This latter dif-
ference in susceptibility could be related to the presence
of a mature monocytic component in FABM4, contrary to
FABM5, which is defined by immature monocytic prolifera-
tion. Indeed, IL-10 has been detected and seems associated
with sHLA-G expression at protein and transcript levels in
pulmonary tumors and cutaneous lymphomas [14,16]. Thus,
IL-10 appears able to induce sHLA-G expression in tropho-
blasts and monocytes [48].
The effect observed with cytokine stimulation in sHLA-G
in some pathology subtypes seems to be partly related to a
more elevated transcript level.
The results of cytokine stimulations led us to investigate if
a particular plasma cytokine profile was characteristic of leu-
kemic patients, knowing that data on this subject are scarce.
Although only IL-10, IL-6, and IFN-g could be detected in
some cases, no conclusion could be drawn. However, we
suggest that the tested cytokines can reach elevated levels
near the site of initial proliferation (i.e., the bone marrow), as-
suming that a large number of cytokines can be synthesized
by the medullar microenvironment.
In acute leukemias, several factors are relevant to prog-
nosis, including cytogenetic abnormalities and myelodyspla-
sia, which are now included in the World Health Organization
classification [49]. The present statistical study failed to re-
veal any correlation with prognosis. However, two biologic
features could be correlated with a high sHLA-G level: ab-
sence of anterior myelodysplasia and high-level leukocytosis
(leukocyte number per unit volume of blood). The inverse
correlation between sHLA-G level and anterior myelodys-
Figure 5. Correlation of sHLA-G plasma levels with clinical biologic criteria. Upper and lower limits represent the 75th and 25th percentiles, respectively. The
middle line indicates medians. (a) Correlation with anterior myelodysplasia. The two boxes represent the following groups: patients without anterior myelodysplasia
and patients with anterior myelodysplasia. ANOVA reveals a significant difference in sHLA-G levels between patients with and patients without anterior
myelodysplasia (P < .01). (b) Correlation with leukocytosis. The two boxes represent the following groups: low-level leukocytosis (<10 g/l) and hyperleukocytosis
(>10 g/l). ANOVA reveals a significant difference in sHLA-G levels between patients with high and patients with low leukocytosis (P < .01).
Figure 4. mRNA levels of the HLA-G transcripts of pathologic cell samples
stimulated by cytokines for 48 hours, as evaluated by real-time quantitative
PCR, quoted relative to mRNA levels of JEG3 (%), with the choriocarcinoma
cell line constitutively expressing HLA-G transcripts. The transcription level of
JEG3 is defined arbitrarily as 100%. (a) Three representative cases (FABM4,
B-ALL, and T-ALL) of pathologies responding to cytokine stimulations as well
as (b) three representative cases of nonresponding pathologies (FABM5,
FABM1, and FABM2) are illustrated by histograms representing HLA-GmRNA
levels according to each condition: (1) control (without stimulation); (2) IFN-c
(500 U/ml); (3) IFN-c (500 U/ml)GM-CSF (100 U/ml); (4) IFN-c (100 U/ml)
GM-CSF (100 U/ml)  IL-2 (220 U/ml); (5) IL-10 (50 ng/ml).
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plasia may appear surprising, considering the poor prog-
nosis impact of this background. However, this finding can
be explained by a potential link between sHLA-G secretion
and a de novo acute leukemic process unrelated to chronic
pathology, such as dysplasia. A correlation between hyper-
leukocytosis and sHLA-G merely reflects the frequent hyper-
cellular pattern of pathologies expressing higher levels
of sHLA-G.
Because membrane-bound and sHLA-G molecules are
well-known for their immunoregulatory actions [50], their
expression could favor tumor escape, as has been shown
in melanomas [11] and gliomas [15]. In this study, we did not
find any correlation with survival or relapse delay. These find-
ings could be related to the relatively lownumber of patients in
the present cohort, in particular in some FAB subtypes. Be-
cause the studied pathologies are strongly acute, the immune
response might not be efficient in time, explaining why no ef-
fect of sHLA-G could be observed over a short delay. It would
be appropriate to carry out a kinetic study to determine the
evolution of sHLA-G level and its potential association with
remission or relapse episodes. The part devoted to HLA-G in
tumor escape remains to be more precisely determined in
these acute pathologies. The mechanisms responsible for
this abnormal secretion should be further examined in a
therapeutic perspective, so that we canmodulate the expres-
sion of sHLA-G molecules in association with other factors.
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